[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fFU3AL10ijt58hYNPwTo-B45SDiYkp5eWHG292P2nRbU":8,"$fUHDOEQmNXy7iQQ7sJzqaERWQXcOEjQDrccusQf7G9Rs":55,"$ftYNRGKXEQfE4X690s0WNhOaqveft64JzQSDd3zHsb1I":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},68594,868808,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//iTCP1DSvplAFJhNCT6SR8jINhAgp8TZa.png","王凯来","浙江大学医学院附属第二医院","肿瘤科","住院医师",20,0,"EGFR-TKI类药物用药实用指南：肺腺癌治疗中的关键细节","","https://ystcdn.venuertc.com/venue/AI/7b6b77eb-02f9-47f3-9464-4559cd02fdd5.jpg","\u003Cdiv class=\"material-guide\">\n  \u003Ch1 id=\"material_title\" class=\"material-title\">EGFR-TKI类药物用药实用指南：肺腺癌治疗中的关键细节\u003C/h1>\n  \u003Cdiv class=\"material-section material-intro\">\n    \u003Cdiv class=\"material-section-bg\">\u003C/div>\n    \u003Cp>\n      说到肿瘤靶向药，有一种被提及率极高，那就是EGFR-TKI类口服小分子抑制剂。这类药物常用于肺腺癌等的治疗。由于其特殊作用机制和服用方式，安全合理使用显得尤为重要。本文会介绍7个核心用药细节，帮助大家正确安全地使用EGFR-TKI药物，避免常见用药风险，让治疗效果最大化。  \n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 01 -->\n  \u003Cdiv class=\"material-section\">\n    \u003Cdiv class=\"material-section-bg\">\u003C/div>\n    \u003Ch2 class=\"material-subtitle\">1️⃣ 剂型与常见规格\u003C/h2>\n    \u003Cp>\n      EGFR-TKI类药物主要有片剂和胶囊形式，通用名如奥希替尼（Osimertinib）、吉非替尼（Gefitinib）、埃克替尼（Icotinib）等。常见规格包括40mg、80mg、250mg等，应严格按照医生或说明书的推荐剂量服用。不同药品的成分和规格可能略有差别，购买和使用前须明确所用药品的具体剂量。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 02 -->\n  \u003Cdiv class=\"material-section\">\n    \u003Cdiv class=\"material-section-bg\">\u003C/div>\n    \u003Ch2 class=\"material-subtitle\">2️⃣ 药物作用机制简介\u003C/h2>\n    \u003Cp>\n      EGFR-TKI作为酪氨酸激酶抑制剂，能够强力抑制特定基因位点（如EGFR 19号外显子缺失突变）产生的异常信号，从而阻断相关细胞的生长。它们属于靶向分子药物，只针对特定分子发挥作用，提升了治疗精准度，并降低了对人体其他细胞的损伤（Liu et al., 2020）。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 03 -->\n  \u003Cdiv class=\"material-section\">\n    \u003Cdiv class=\"material-section-bg\">\u003C/div>\n    \u003Ch2 class=\"material-subtitle\">3️⃣ 正确服用时间与方法\u003C/h2>\n    \u003Cp>\n      大多数EGFR-TKI类药物建议每天一次、定时口服，具体服药时间取决于药品类型。部分药品可以空腹服用，也有的需饭后口服，应根据说明书或医师建议执行。例如：奥希替尼80mg每日一次，可空腹或餐后服用；吉非替尼250mg每日一次，餐前餐后皆可。\n    \u003C/p>\n    \u003Cp>\n      正确做法：吞服整片，不要咀嚼或掰碎。用足量温水（约200ml）送服。特殊情况下若吞咽有困难，可参看说明书是否允许分散或混悬服用，但严禁自行改变给药方式。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 04 -->\n  \u003Cdiv class=\"material-section\">\n    \u003Cdiv class=\"material-section-bg\">\u003C/div>\n    \u003Ch2 class=\"material-subtitle\">4️⃣ 用药剂量调整和变更\u003C/h2>\n    \u003Cp>\n      EGFR-TKI类药品应遵从起始剂量，随访期间如出现严重不良反应或特殊生理变化，需由医生调整剂量或更换药物。切勿自行增减用量。体重、肝肾功能异常者，有时需要剂量下调。\n    \u003C/p>\n    \u003Cp>\n      举例：一位52岁男性患者因出现中度皮疹和口腔黏膜反应，经医生评价后，将奥希替尼从每日80mg减至40mg，副作用明显减轻，治疗也顺利进行。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 05 -->\n  \u003Cdiv class=\"material-section\">\n    \u003Cdiv class=\"material-section-bg\">\u003C/div>\n    \u003Ch2 class=\"material-subtitle\">5️⃣ 典型药物相互作用 ⚠️\u003C/h2>\n    \u003Cp>\n      EGFR-TKI药物易与其他药品发生相互作用，影响疗效或副作用风险。常见如下：\n    \u003C/p>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\u003Cb>与强酸抑制剂\u003C/b>（如奥美拉唑）同服，可能降低某些EGFR-TKI药物吸收率，应尽量错开6-12小时。\u003C/li>\n      \u003Cli>\u003Cb>含酮康唑等CYP3A4抑制/诱导药\u003C/b>，会显著改变TKI类药物的血药浓度，须告知医生所有正在使用的药品。\u003C/li>\n      \u003Cli>与抗生素、抗真菌药、抗癫痫药联用时，提前咨询医生。\u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      正确做法：每次开新药时及时提醒医师当前正在服用的TNKI药物，避免私自联合其他药物。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 06 -->\n  \u003Cdiv class=\"material-section\">\n    \u003Cdiv class=\"material-section-bg\">\u003C/div>\n    \u003Ch2 class=\"material-subtitle\">6️⃣ 特殊人群用药须知\u003C/h2>\n    \u003Cp>\n      不同患者的用药需求可能不同，特殊人群用药需特别警惕：\n    \u003C/p>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\u003Cb>肝肾功能不全患者\u003C/b>：部分药物可能因代谢减慢导致血药浓度升高，须根据功能参数酌情减量或延长服药间隔。\u003C/li>\n      \u003Cli>\u003Cb>老年人\u003C/b>：易感不良反应，应从低剂量起用并密切监测。\u003C/li>\n      \u003Cli>\u003Cb>孕妇与哺乳期妇女\u003C/b>：EGFR-TKI药物已被建议避免在妊娠和哺乳期使用，因可能对胎儿或婴儿带来风险。\u003C/li>\n      \u003Cli>\u003Cb>儿童\u003C/b>：尚无足够的数据证实安全性和有效性，通常不推荐应用于儿童。\u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      切记个体化调整必须在医生指导下完成，切忌自行调整！\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 07 -->\n  \u003Cdiv class=\"material-section\">\n    \u003Cdiv class=\"material-section-bg\">\u003C/div>\n    \u003Ch2 class=\"material-subtitle\">7️⃣ 常见不良反应及处理方法\u003C/h2>\n    \u003Cp>\n      服用EGFR-TKI后，部分患者会出现皮疹、腹泻、口腔炎、指甲问题等副作用，根据说明书数据，这类药物中皮肤相关不良反应发生率可达75%以上（Jänne et al., 2015）。\n    \u003C/p>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\u003Cb>皮疹\u003C/b>：轻度可外用保护性药膏，重度时需请医生评估，必要时调整剂量。\u003C/li>\n      \u003Cli>\u003Cb>腹泻\u003C/b>：充足补液，轻中度可用止泻药，严重时暂停用药并就医。\u003C/li>\n      \u003Cli>\u003Cb>肝酶升高/间质性肺炎\u003C/b>：如发现乏力、气促或皮肤发黄，必须尽快就医并停药。\u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      正确做法：出现上述情况时，要主动联系医护人员，切勿自行停药或擅自使用其他药物掩盖症状。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 08 -->\n  \u003Cdiv class=\"material-section\">\n    \u003Cdiv class=\"material-section-bg\">\u003C/div>\n    \u003Ch2 class=\"material-subtitle\">8️⃣ 储存条件和药品有效期\u003C/h2>\n    \u003Cp>\n      所有EGFR-TKI药物均应贮存在干燥、避光、温度不高于25℃处（根据各自说明书标准），避免接触儿童，远离高温潮湿环境。密封储存，启封后应尽快使用。过期药品请按照说明书或医疗机构要求进行弃置，不可擅自丢弃。\n    \u003C/p>\n    \u003Cp>\n      小贴士：切勿将药品敞开放在冰箱，防潮易失效；也不要与其他药品放在同一瓶中混用。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 09 -->\n  \u003Cdiv class=\"material-section\">\n    \u003Cdiv class=\"material-section-bg\">\u003C/div>\n    \u003Ch2 class=\"material-subtitle\">9️⃣ 漏服与过量处理\u003C/h2>\n    \u003Cp>\n      偶尔漏服：发现后如果距离下次服药还有较长时间，尽快补服一次；如临近下次服用则跳过本次，切勿加倍剂量弥补。连续漏服建议主动咨询医师。\u003Cbr/>\n      过量服用：一旦误服过量，注意监测是否出现新发不适，并第一时间前往医疗机构，带上剩余药品及包装，便于医师判断。\n    \u003C/p>\n    \u003Cdiv class=\"material-blockquote\">\n      \u003Cspan class=\"material-emoji\">📌\u003C/span> 正确做法：定时定量服药，设置手机提醒，尽量固定每天同一时间服用，养成良好用药习惯。\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- 10 -->\n  \u003Cdiv class=\"material-section\">\n    \u003Cdiv class=\"material-section-bg\">\u003C/div>\n    \u003Ch2 class=\"material-subtitle\">🔟 用药案例分享\u003C/h2>\n    \u003Col class=\"material-list\">\n      \u003Cli>\n        一位52岁男性，服用奥希替尼期间出现轻度腹泻和皮疹，经医生指导后调整饮食、减量用药，不良反应控制良好，服药习惯未间断。\n      \u003C/li>\n      \u003Cli>\n        临床上有患者因长期与强酸抑制剂同服，药效明显减弱，改为分时段服用，两药间隔8小时后，疗效恢复正常。\n      \u003C/li>\n      \u003Cli>\n        有老年患者服用埃克替尼时，因未按医嘱每日定时、定量服药，疗效波动较大。经家属协助用药提醒后，坚持规律服用，效果趋于稳定。\n      \u003C/li>\n    \u003C/ol>\n  \u003C/div>\n\n  \u003C!-- 结语 -->\n  \u003Cdiv class=\"material-section material-conclusion\">\n    \u003Cdiv class=\"material-section-bg\">\u003C/div>\n    \u003Ch2 class=\"material-subtitle\">小结与用药提醒 📝\u003C/h2>\n    \u003Cp>\n      EGFR-TKI类药物以其靶向性强、疗效明确而被广泛应用，但用药的每一步都必须精准到位。严格按照剂量服药、注意联合用药风险、及时管理不良反应，是安全使用的三大准则。\u003Cb>如果遇到任何疑问，建议及时咨询医生或药师，不要自行更改用药方案。\u003C/b>\n    \u003C/p>\n    \u003Cul class=\"material-list\">\n      \u003Cli>固定时间，正确方式服药；\u003C/li>\n      \u003Cli>发生副作用及时就诊；\u003C/li>\n      \u003Cli>避免擅自增减、联合其他药物；\u003C/li>\n      \u003Cli>用药期间密切与医护沟通。\u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      安全合理用药，是每一位患者和家庭的健康守护线。做好用药细节，才能让药物真正发挥最大价值。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 参考文献 -->\n  \u003Cdiv class=\"material-section material-ref\">\n    \u003Cdiv class=\"material-section-bg\">\u003C/div>\n    \u003Ch2 class=\"material-subtitle\">参考文献 References\u003C/h2>\n    \u003Col class=\"material-list\">\n      \u003Cli>\n        Liu, Y., Zhang, L., Li, L., & Cui, J. (2020). Overview of the Development of EGFR-Tyrosine Kinase Inhibitor for Non-Small Cell Lung Cancer. \u003Ci>Journal of Cancer Research and Clinical Oncology\u003C/i>, \u003Cb>146\u003C/b>(3), 691–701.\n      \u003C/li>\n      \u003Cli>\n        Jänne, P. A., Yang, J. C.-H., Kim, D.-W., et al. (2015). AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer. \u003Ci>New England Journal of Medicine\u003C/i>, \u003Cb>372\u003C/b>(18), 1689-1699.\n      \u003C/li>\n      \u003Cli>\n        Mok, T. S., Wu, Y.-L., Thongprasert, S., et al. (2009). Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. \u003Ci>New England Journal of Medicine\u003C/i>, \u003Cb>361\u003C/b>(10), 947-957.\n      \u003C/li>\n    \u003C/ol>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.material-guide {\n  font-family: 'Segoe UI', 'Arial', 'PingFang SC', 'Hiragino Sans GB', 'Microsoft YaHei', sans-serif;\n  color: #24455e;\n  background: #f8fafd;\n  padding: 48px 12% 40px 12%;\n  box-sizing: border-box;\n  line-height: 1.85;\n  max-width: 900px;\n  margin: 0 auto;\n}\n.material-title {\n  font-size: 2.1rem;\n  font-weight: 700;\n  color: #183861;\n  padding: 36px 0 20px 0;\n  text-align: left;\n}\n.material-section {\n  margin-top: 38px;\n  margin-bottom: 20px;\n  padding: 32px 38px 28px 38px;\n  border-radius: 20px;\n  background: #ffffff;\n  position: relative;\n  box-shadow: 0 2px 8px #ecf1f6;\n}\n.material-section-bg {\n  position: absolute;\n  left: 0;\n  top: -18px;\n  width: 105%;\n  height: 52px;\n  background: linear-gradient(80deg, #e8f1fa 55%, #fafdff 100%);\n  opacity: .71;\n  border-radius: 18px 18px 48px 48px;\n  z-index: 0;\n}\n.material-section > * {\n  position: relative;\n  z-index: 1;\n}\n.material-intro {\n  background: linear-gradient(100deg, #e9f5ff 70%, #fafdff 100%);\n  box-shadow: none;\n}\n.material-subtitle {\n  font-size: 1.32rem;\n  font-weight: 600;\n  color: #1976d2;\n  margin: 0 0 22px 0;\n  letter-spacing: 0.03em;\n}\n.material-list {\n  margin: 10px 0 14px 20px;\n  padding: 0;\n  font-size: 1.05rem;\n}\n.material-list li {\n  margin-bottom: 10px;\n  list-style-type: disc !important;\n}\n.material-blockquote {\n  background: #eef5fa;\n  border-left: 4px solid #1976d2;\n  padding: 14px 20px;\n  margin-top: 22px;\n  font-size: 1.01rem;\n  color: #2b4475;\n  border-radius: 6px 2px 2px 6px;\n  display: flex;\n  align-items: center;\n}\n.material-blockquote .material-emoji {\n  font-size: 1.34rem;\n  margin-right: 12px;\n}\n.material-conclusion {\n  background: linear-gradient(95deg, #f1fdfb 70%, #fafdff 100%);\n}\n.material-ref {\n  background: #f3f6f8;\n  color: #345166;\n}\n.material-ref .material-subtitle {\n  color: #2967a2;\n}\n.material-ref .material-list {\n  font-size: 0.98rem;\n}\n@media (max-width: 700px) {\n  .material-guide {\n    padding: 14px 2% 24px 2%;\n    font-size: 0.95rem;\n  }\n  .material-title {\n    font-size: 1.19rem;\n    padding: 20px 0 13px 0;\n  }\n  .material-section {\n    padding: 16px 10px 14px 10px;\n    border-radius: 14px;\n  }\n  .material-section-bg {\n    height: 32px;\n    border-radius: 13px 13px 20px 20px;\n  }\n  .material-subtitle {\n    font-size: 1.08rem;\n    margin-bottom: 11px;\n  }\n}\n\u003C/style>","\u003Cdiv class=\"material-guide\">\n  \u003Ch1 id=\"material_title\" class=\"material-title\">EGFR-TKI类药物用药实用指南：肺腺癌治",522,"2025-10-28 00:01:12","EGFR-TKI, 肺腺癌, 药物用法, 副作用, 安全用药","深入了解EGFR-TKI类药物在肺腺癌治疗中的关键细节，安全有效用药，最小化风险，最大化治疗效果。适合患者及家属阅读！","2025-11-14 23:30:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]